Accelerating phase 2 clinical development with real-world data (RWD): An external control arm (ECA) pilot in HER2-positive (HER2+) metastatic breast cancer (mBC). This is an ASCO Meeting Abstract from ...

The long term use of proton pump inhibitors (PPIs), a class of drugs widely used to treat acid reflux and ulcers, may not be linked to any increased risk of developing gastric (stomach) cancer, finds ...

TOKYO, Jun 2, 2025 - (JCN Newswire) - - Eisai Co., Ltd. announced today the launch of "Pariet S" (pharmaceutical requiring guidance), which is highly effective in alleviating severe heartburn ...

Long-term risks of proton pump inhibitors for acid reflux and heartburn ...

Proton-pump inhibitors (PPIs) are frequently prescribed to suppress stomach acid in patients with gastroesophageal reflux disease (GERD). Prescribing rates of PPIs in children have risen more than 500 ...

Nearly 70% of patients with acute upper gastrointestinal (GI) bleeding and low-risk or no peptic ulcer disease received intravenous (IV) proton pump inhibitors (PPIs) inappropriately, leading to ...

Alcohol-related hospitalizations among patients with cancer in the United States: Trends and associated risk factors. Sequentially adjusted survey-weighted Cox models estimating the cause-specific ...

Please provide your email address to receive an email when new articles are posted on . An intervention program was associated with an absolute reduction of 7.3% in patients who filled proton pump ...

Baseline use of proton pump inhibitors (PPIs) was associated with future bronchiectasis exacerbations, based on new data from more than 3000 individuals presented at the World Bronchiectasis ...

"The finding of no association may offer relief for patients who need long-term proton pump inhibitor therapy in the treatment of gastroesophageal reflux disease or for other clear indications." ...